Literature DB >> 33627788

Maternal use of sedative drugs and its effects on pregnancy outcomes: a Finnish birth cohort study.

Satu-Maarit Björkstedt1,2, Hannu Kautiainen1,3,4, Ulla Tuomi5, Mika Gissler6,7, Pirjo Pennanen8, Johan G Eriksson1,3,9,10, Merja K Laine11,12.   

Abstract

Our aim was to evaluate maternal use of sedative drugs before, during, and after pregnancy and to assess the influence of use of these drugs on pregnancy outcomes. The study cohort (N = 6231) consists of all primiparous women, who lived in the city of Vantaa, Finland, and who delivered a singleton between 2009 and 2015. Data were obtained from Finnish national health registers. Of the women, 3.2% (n = 202) purchased at least once sedative drugs within 90 days before conception, during pregnancy and/or within 90 days after delivery. Sedative drug users were older, less likely to cohabitate, more often smokers, had lower educational attainment and had more mental diseases (for all p < 0.001) compared with non-users. Sedative drug users purchased more often antidepressants and drugs for the alimentary tract, musculoskeletal and nervous system than non-users (for all p < 0.001). No adverse birth or pregnancy outcomes were found in the group using sedative drugs compared with the non-users. Studies in larger cohorts are needed to confirm our study findings.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33627788      PMCID: PMC7904770          DOI: 10.1038/s41598-021-84151-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).

Authors:  Jamie R Daw; Barbara Mintzes; Michael R Law; Gillian E Hanley; Steven G Morgan
Journal:  Clin Ther       Date:  2011-12-14       Impact factor: 3.393

Review 2.  ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.

Authors: 
Journal:  Obstet Gynecol       Date:  2008-04       Impact factor: 7.661

3.  Ponderal index for discrimination between symmetric and asymmetric growth restriction: percentiles for neonates from 30 weeks to 43 weeks of gestation.

Authors:  Eva Landmann; Irwin Reiss; Björn Misselwitz; Ludwig Gortner
Journal:  J Matern Fetal Neonatal Med       Date:  2006-03

4.  Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics.

Authors:  Birgitta Norstedt Wikner; Carl-Olav Stiller; Bengt Källén; Charlotte Asker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-09       Impact factor: 2.890

Review 5.  Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.

Authors:  J H Kanto
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

6.  Perinatal anxiety disorder prevalence and incidence.

Authors:  Nichole Fairbrother; Patricia Janssen; Martin M Antony; Emma Tucker; Allan H Young
Journal:  J Affect Disord       Date:  2016-04-14       Impact factor: 4.839

7.  Dispensing of benzodiazepines and benzodiazepine-related drugs to pregnant women: a population-based cohort study.

Authors:  Brit Solvor Riska; Svetlana Skurtveit; Kari Furu; Anders Engeland; Marte Handal
Journal:  Eur J Clin Pharmacol       Date:  2014-09-11       Impact factor: 2.953

8.  Use of prescribed drugs among primiparous women: an 11-year population-based study in Denmark.

Authors:  Anne-Mette Bay Bjørn; Mette Nørgaard; Heidi Holmager Hundborg; Ellen Aagaard Nohr; Vera Ehrenstein
Journal:  Clin Epidemiol       Date:  2011-05-02       Impact factor: 4.790

9.  Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance.

Authors:  Gillian E Hanley; Barbara Mintzes
Journal:  BMC Pregnancy Childbirth       Date:  2014-07-22       Impact factor: 3.007

Review 10.  A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD).

Authors:  J R Davidson; W Zhang; K M Connor; J Ji; K Jobson; Y Lecrubier; A C McFarlane; D J Newport; D J Nutt; D N Osser; D J Stein; Z N Stowe; O Tajima; M Versiani
Journal:  J Psychopharmacol       Date:  2008-10-02       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.